Vanda Pharmaceuticals Inc (VNDA)

15.95
NASDAQ : Health Care
Prev Close 15.90
Day Low/High 15.75 / 16.40
52 Wk Low/High 6.91 / 18.00
Avg Volume 746.80K
Exchange NASDAQ
Shares Outstanding 43.95M
Market Cap 698.75M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In Vanda Pharmaceuticals Increases 10.2%

Short Interest In Vanda Pharmaceuticals Increases 10.2%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 272,221 share increase in total short interest for Vanda Pharmaceuticals Inc , to 2,933,249, an increase of 10.23% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals is Now Oversold (VNDA)

Vanda Pharmaceuticals is Now Oversold (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Vanda Pharmaceuticals At $12, Earn 12.7% Annualized Using Options

Commit To Buy Vanda Pharmaceuticals At $12, Earn 12.7% Annualized Using Options

Investors considering a purchase of Vanda Pharmaceuticals Inc stock, but tentative about paying the going market price of $15.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $12 strike, which has a bid at the time of this writing of 95 cents.

Vanda Pharmaceuticals Settles Fanapt® Patent Litigation With Taro

Vanda Pharmaceuticals Settles Fanapt® Patent Litigation With Taro

Vanda Grants Taro a license to sell generic Fanapt® beginning November 2027

Vanda Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 2, 2016

Vanda Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 2, 2016

Conference Call and Webcast to Follow

Notable Thursday Option Activity: VNDA, AIRM, LL

Notable Thursday Option Activity: VNDA, AIRM, LL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vanda Pharmaceuticals Inc , where a total volume of 13,322 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 127.7% of VNDA's average daily trading volume over the past month, of 1.0 million shares.

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

JMP Securities increased Vanda Pharma's (VNDA) stock price target to $22 from $18 after a judge ruled that a generic drug maker's medication violated the company's patents.

Vanda Pharmaceuticals Stock Sees Short Interest Fall 13%

Vanda Pharmaceuticals Stock Sees Short Interest Fall 13%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 396,865 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 2,647,162, a decrease of 13.04% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

A Delaware court ruled Thursday that Roxane Laboratories ANDA product infringes against several Vanda Pharmaceuticals (VNDA) patents for schizophrenia drug Fanapt.

Notable Friday Option Activity: VNDA, BKE, LLNW

Notable Friday Option Activity: VNDA, BKE, LLNW

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vanda Pharmaceuticals Inc , where a total of 4,311 contracts have traded so far, representing approximately 431,100 underlying shares. That amounts to about 90.2% of VNDA's average daily trading volume over the past month of 477,680 shares.

HETLIOZ® Is Now Available For The Treatment Of Non-24-Hour Sleep-Wake Disorder In Germany

HETLIOZ® Is Now Available For The Treatment Of Non-24-Hour Sleep-Wake Disorder In Germany

- HETLIOZ® (tasimelteon) is the first and only product to receive approval for the treatment of Non-24 in the European Union

Interesting VNDA Call Options For March 2017

Interesting VNDA Call Options For March 2017

Investors in Vanda Pharmaceuticals Inc saw new options become available today, for the March 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vanda Pharmaceuticals To Announce Second Quarter 2016 Financial Results On July 27, 2016

Vanda Pharmaceuticals To Announce Second Quarter 2016 Financial Results On July 27, 2016

Conference Call and Webcast to Follow

Vanda Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

Vanda Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

Presentation will be Webcast Live and Archived on Vanda's Website

Vanda Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Vanda Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Presentation will be Webcast Live and Archived on Vanda's Website

Vanda Pharmaceuticals Stock Sees Short Interest Drop 13%

Vanda Pharmaceuticals Stock Sees Short Interest Drop 13%

The most recent short interest data has been released for the 05/13/2016 settlement date, which shows a 654,026 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 4,420,764, a decrease of 12.89% since 04/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals Stock Sees Short Interest Drop 11.4%

Vanda Pharmaceuticals Stock Sees Short Interest Drop 11.4%

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 650,935 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 5,074,790, a decrease of 11.37% since 04/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 16% Annualized Using Options

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 16% Annualized Using Options

Investors considering a purchase of Vanda Pharmaceuticals Inc stock, but cautious about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 70 cents.

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

Vanda Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 4, 2016

Vanda Pharmaceuticals To Announce First Quarter 2016 Financial Results On May 4, 2016

Conference Call and Webcast to Follow

Short Interest Moves 14.3% Lower For VNDA

Short Interest Moves 14.3% Lower For VNDA

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 1,020,996 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 6,127,734, a decrease of 14.28% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

Interesting VNDA Put And Call Options For September 16th

Interesting VNDA Put And Call Options For September 16th

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.